What Drug Manufacturers Should Watch in the Wake of Natural Disasters
When it comes to natural disasters, it’s not about if your supply chain will be impacted, it’s when.
For the life sciences industry, the consequences of supply chain disruption become a public safety concern. Like 1998’s Hurricane George, Hurricanes Irma and Maria have underlined this concern. Following the storms, the FDA announced that the U.S. will likely experience drug shortages due to the natural disasters’ residual impact on the drug manufacturing industry in Puerto Rico.
Nearly 10 percent of drugs prescribed in the U.S. are manufactured in Puerto Rico. Those include critically important products like treatments for cancer, HIV and rheumatoid arthritis. More than 50 medical device plants are located in Puerto Rico, manufacturing more than 1,000 types of medical devices and employing 18,000 people. Only a small fraction of the power to the island has been restored, suggesting many drug and device manufacturers may not be fully online. FDA Commissioner Scott Gottlieb told Reuters, “It’s unclear when they are going to be able to bring [production] up to full capacity.”
On Oct. 20, the FDA released a statement outlining efforts in conjunction with federal and local agencies to rebuild the island, monitoring more than 40 medical devices manufactured there and working alongside pharmaceutical and medical device makers to expedite the process of getting factories back up and running.
While many factories owned by large global pharmaceutical companies are running on generator power as backup, some of these plants may be the single manufacturer of a certain device type. The FDA said it is working with about 10 manufacturers, especially those manufacturing critical blood-related medical devices, which fall within this camp.
Outcomes & Reimbursement
If providers don’t have access to the right drugs or devices, they could face adverse financial impacts including greater costs associated with delivering patient care through higher drug acquisition and personal costs. They may also have to prescribe an alternate drug that isn’t as effective. That leads to implications for the effectiveness of care and potentially a hit to quality metrics, which would impact reimbursement under value-based arrangements, including those taking place under the Medicare Access and CHIP Reauthorization Act (MACRA). Providers who might be up against a shortage should work to understand what that could mean for their ability to attract investors.
Business Continuity Risk
The revenue disruption also poses an audit risk for pharmaceutical and medical device companies. If a plant is destroyed or not operating at full capacity and providers are forced to turn to other suppliers for critical drug products, like cancer treatments, it could create a going concern of business continuity issues pharma or medical device company.
For life sciences, natural disaster and supply chain risks are hardly new but Hurricanes Irma and Maria should serve as a stark reminder on the importance of disaster preparedness and supply chain balance. Many factories selected sites in Puerto Rico to take advantage of significant tax benefits, but those benefits of a reduced tax burden will no longer outweigh the supply chain risk associated with production that’s concentrated to a single area. Looking ahead, pharmaceutical and device manufacturers — even those that haven’t been directly impacted by the disruptions in Puerto Rico — would be wise to reevaluate supply chain risk.Start with a broad risk assessment. This should begin at the top level of the organization, with an analysis of the risk related to natural disasters throughout the drug and device manufacturing process, including analysis of supply chain, regulatory and reputation risks to which the company may be exposed. As natural disaster events persist, manufacturers should consider prioritizing these risk assessments. They can help them start to address short- and long-term threats, and create and implement manageable changes and solutions within both their supply chains and their production processes.Pharmaceutical and medical device manufacturers can also take proactive steps to make plants more secure. Infrastructure investments for hurricane and fire proofing or building remote storage, away from natural disaster-prone regions, will more than pay for themselves if and when catastrophe strikes.Liability, property and equipment insurance can also help to protect against these events. Pharmaceutical and medical device manufacturers make large investments in specialized equipment and warehousing space. Whether it’s a small flood or a Category 5 hurricane, property and equipment insurance can minimize the impact to operations.Pharma and device manufacturers should also ensure they are diversifying their suppliers and, perhaps most importantly, their production locations. This can help more adequately develop a supply chain able to withstand extreme weather. For investors in the space, conducting regular due diligence on supply chain risk is recommended.The first several weeks following a big storm, businesses that are properly covered by insurance are likely beginning to check off steps on their emergency preparedness checklist. Those that don’t have developed contingency plans, or are noticing gaps in their path forward, should consider incorporating the below next steps for coping with disaster and picking up the pieces.
For more information on the matters discussed above, please contact us.
Material discussed in this communication is meant to provide general information and should not be acted on without obtaining professional advice tailored to you or your company’s individual and specific needs. Any tax advice contained in this communication (including any attachments) is not intended or written to be used, and cannot be used by any person or entity, for the purpose of (i) avoiding penalties that may be imposed on any taxpayer or (ii) promoting, marketing or recommending to another party any transaction or matter addressed herein. This information is for general guidance only and is not a substitute for professional advice.
The information contained herein should not be construed as personalized investment advice. Investment in securities involves the risk of loss, and past performance is no guarantee of future results. There is no guarantee that the views and opinions expressed in this document will come to pass. Historical performance results for investment indexes and/or categories generally do not reflect the deduction of transaction and/or custodial charges or the deduction of an investment-management fee, the incurrence of which would have the effect of decreasing historical performance results. There can be no assurances that your portfolio will match or outperform any particular benchmark.
Information presented is believed to be factual and up-to-date; however, MFA makes no guarantee as to accuracy, completeness, suitability, or validity of any information within this communication and will not be liable for any errors, omissions, or delays in this information or any losses, injuries, or damages from its display or use. Any forward-looking statements are believed to be reasonable; however, MFA gives no assurance that such expectations will prove to be correct.